E. David Ballard

Statistics

Publications

Citations

659

H-Index

Active since

2002

Affiliations

University of California San Diego(Current)

John Radcliffe Hospital

Ferring Pharmaceuticals (Switzerland)

Cosmo Pharmaceuticals (Italy)

Cosmo Pharmaceuticals (Ireland)

E. David Ballard is an author at University of California San Diego specializing in gastrointestinal pharmacotherapy, pharmacotherapy, and ulcerative colitis pharmacotherapy.

Publications per year

2002–2015

Publications

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study

Simon Travis, Silvio Danese, Limas Kupčinskas et al. · Gut · 2013 · 260 citations · Full text

Pharmacy, Pharmacotherapy, Gastroenterology +14

Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study

William J. Sandborn, Simon Travis, Luigi Moro et al. · Gastroenterology · 2012 · 245 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +12

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies

William J. Sandborn, Silvio Danese, G. D’Haens et al. · Alimentary Pharmacology & Therapeutics · 2015 · 78 citations · Full text

Pharmacy, Pharmacotherapy, Gastroenterology +15

Evidence for Therapeutic Equivalence of Lansoprazole 30mg and Esomeprazole 40mg in the Treatment of Erosive Oesophagitis

Colin W. Howden, E. David Ballard, Weining Robieson · Clinical Drug Investigation · 2002 · 57 citations

Medicine, Pharmacology, Pharmacotherapy +10

Su2080 Efficacy of Budesonide MMx(r) 6 mg QD for the Maintenance of Remission in Patients With Ulcerative Colitis: Results From a Phase III, 12 Month Safety and Extended use Study

William J. Sandborn, Silvio Danese, E. David Ballard et al. · Gastroenterology · 2012 · 19 citations

Pharmacy, Pharmacotherapy, Gastrointestinal Pharmacotherapy +11

1–5 of 5